Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Signs and Symptoms Clear all
Recruiting Phase 1 Interventional

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

NCT04617522
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor, Liver Failure
Interventions
Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

NCT07099222
View directory record Official record
Conditions
Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions
Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Recruiting Not applicable Interventional

ACT With CF Self-Help Toolkit

NCT07436351
View directory record Official record
Conditions
Cystic Fibrosis (CF), Depressive and Anxiety Disorders, Psychological Flexibility
Interventions
ACT with CF Self-Help Toolkit, Waitlist
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Not applicable Interventional Results available

Erythromycin in Parkinson's Disease

NCT02005029
View directory record Official record
Conditions
Parkinson's Disease, Levodopa
Interventions
Erythromycin, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?

NCT00067756
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
4-PBA
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome

NCT02681666
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome, IBS
Interventions
Dietary intervention, Irritable Bowel Syndrome eating awareness training
Dietary Supplement · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Yogurt Study in Children 2-4 Years Old Attending Daycare

NCT00760851
View directory record Official record
Conditions
Infections, Respiratory, Diarrhea
Interventions
probiotic strain Bb-12, no Bb-12
Other
Lead sponsor
Georgetown University
Other
Eligibility
2 Years to 4 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

NCT00501722
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
satavaptan (SR121463B)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2009 · Synced Oct 15, 2026, 8:09 AM EDT
Not listed Not applicable Interventional

Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment

NCT04880473
View directory record Official record
Conditions
Gastrointestinal Complication
Interventions
PrevisEA device
Device
Lead sponsor
Entac Medical Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Orlando, Florida • Chicago, Illinois • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 15, 2026, 8:09 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis

NCT01442454
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
chronic pancreatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

NCT01853254
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
View directory record Official record
Conditions
Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions
Civacir® 10%
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 8:09 AM EDT
Not listed Phase 4 Interventional

Curing HCV in Incarcerated Patients

NCT03018353
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Patients receiving Sof/Vel (Epclusa) and Navigation services
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 15, 2026, 8:09 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders

NCT06565637
View directory record Official record
Conditions
Eating Disorders, Sexual Minorities
Interventions
Promoting Resilience to Improve Disordered Eating
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Auburn, Alabama • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 1Phase 2 Interventional

Stage IV Colorectal CA ALIMTA

NCT00166465
View directory record Official record
Conditions
Locally Advanced Unresectable or Stage IV Colorectal Cancer
Interventions
ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 15, 2026, 8:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Understanding Mechanisms of Normal and Disordered Defecation

NCT03842007
View directory record Official record
Conditions
Constipation
Interventions
Rectal Barostat Study, Fecoflowmetry
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

NCT02177136
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Not applicable Interventional

Endoscopic Full Thickness Biopsy, Gastric Wall.

NCT01650714
View directory record Official record
Conditions
Gastroparesis
Interventions
Full thickness gastric biopsy, Full thickness gastric biopsy
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 15, 2026, 8:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Breathe Light Study

NCT01976455
View directory record Official record
Conditions
Over-eating, Obesity
Interventions
20% fewer calories, 40% fewer calories
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 15, 2026, 8:09 AM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Binge Eating in Obese Patients in Primary Care

NCT00537810
View directory record Official record
Conditions
Obesity, Binge Eating
Interventions
Sibutramine, Placebo, Self-help CBT + Sibutramine, Self-help CBT + Placebo
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 15, 2026, 8:09 AM EDT
Terminated Phase 3 Interventional

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

NCT04231279
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome
Interventions
synthetic human secretin
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
6 Months to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 15, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals

NCT00300742
View directory record Official record
Conditions
Alcohol Dependence, Binge Eating
Interventions
Topiramate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 15, 2026, 8:09 AM EDT